Bristol-Myers Squibb stock drops 6% after FDA delays approval deadline for cancer drug

Bristol-Myers Squibb Co. shares dropped nearly 6% in extremely heavy Monday morning trade after the company said that, because of new information from a cancer clinical trial, the U.S. Food and Drug Administration is extending the review period for the company's new drug application by three months.